Holen Sie sich die Stockscreener-App
33.76
3.46%
-1.21
Handel nachbörslich:
33.15
-0.61
-1.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$34.97
Offen:
$34.86
24-Stunden-Volumen:
2.07M
Relative Volume:
0.96
Marktkapitalisierung:
$5.36B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-306.91
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
-8.02%
1M Leistung:
+6.08%
6M Leistung:
-6.17%
1J Leistung:
+54.65%
1-Tages-Spanne:
$33.10
$35.01
1-Wochen-Bereich:
$33.10
$37.45
52-Wochen-Spanne:
$21.65
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.76 | 5.55B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Is TG Therapeutics Inc. stock bottoming outJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Market reaction to TG Therapeutics Inc.’s recent newsMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
How risky is TG Therapeutics Inc. (NKB2) stock compared to peersJuly 2025 Levels & Safe Capital Investment Plans - newser.com
What makes TG Therapeutics Inc. (NKB2) stock appealing to growth investorsMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Is TG Therapeutics Inc. still worth holding after the dipJuly 2025 Retail & Verified Chart Pattern Trade Signals - newser.com
Is TG Therapeutics Inc. reversing from oversold territoryMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
What indicators show strength in TG Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - newser.com
Analysts Offer Predictions for TG Therapeutics Q3 Earnings - MarketBeat
What analysts say about TG Therapeutics Inc stockEarnings Forecast Updates & Identify Breakout Stocks - earlytimes.in
TG Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
HC Wainwright Weighs in on TG Therapeutics FY2029 Earnings - MarketBeat
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption - MSN
Is TG Therapeutics Inc. forming a bottoming baseMarket Performance Report & Reliable Entry Point Alerts - newser.com
TGTX Receives 'Buy' Rating from HC Wainwright & Co. with $60 Pri - GuruFocus
Analyzing TG Therapeutics Inc. with risk reward ratio chartsQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Detecting support and resistance levels for TG Therapeutics Inc.July 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain - Yahoo Finance
What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders - Yahoo Finance
A Look at TG Therapeutics (TGTX) Valuation Following Positive Six-Year BRIUMVI Trial Results - Sahm
TG Therapeutics, Inc.'s (NASDAQ:TGTX) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 5.8% Over Last Week - 富途牛牛
Key metrics from TG Therapeutics Inc.’s quarterly dataTrade Volume Summary & Precise Buy Zone Identification - newser.com
Can TG Therapeutics Inc. stock rebound after recent weaknessBear Alert & Real-Time Stock Movement Alerts - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - Sahm
Is TG Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside - DirectorsTalk Interviews
TG Therapeutics, Inc. (TGTX) Investor Outlook: Riding On A 92.10% Revenue Growth Wave - DirectorsTalk Interviews
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
What drives TG Therapeutics Inc stock priceGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Is TG Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Demo Trading Rooms Open Daily - Early Times
TG Therapeutics (TGTX) Is Up 9.7% After Six-Year BRIUMVI MS Data Shows Sustained Efficacy and Safety - Sahm
Tg Therapeutics And Ke Holdings Top The Bull Strangle Watch List For This Week - Barchart.com
TG Therapeutics’ MS drug shows low relapse rate after six years - Investing.com Nigeria
TG Therapeutics’ MS drug shows low relapse rate after six years By Investing.com - Investing.com South Africa
TGTX Shares Rise on Promising Six-Year Data from ULTIMATE Trials - GuruFocus
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):